Scandion Oncology A/S receives EU-patent for SCO-101Scandion Oncology A/S (“Scandion Oncology”) today announces that ...
Scandion Oncology applies for start of clinical Phase II trial in patients with metastatic colorectal cancerScandion Oncology A/S (“Scandion Oncology”) today announces that ...
In vivo animal data report on antibiotic resistance extended until mid-Q4 2019Scandion Oncology A/S (“Scandion Oncology”) today announces that ...
Peter Høngaard new Chairman of the Board in Scandion OncologyScandion Oncology A/S (“Scandion Oncology”) today announces that ...
Scandion Oncology CEO Newsletter autumn 2019Dear Scandion Oncology shareholder, Scandion Oncology is heading towards an ...
Flagging notification in Scandion Oncology A/SScandion Oncology A/S (”Scandion Oncology”) hereby announces that, in connect...
Half-Year Report 1 January 2019 - 30 June 2019Scandion Oncology A/S (”Scandion Oncology” or the “Company”) hereby publishes...
Update on Q & AScandion Oncology wishes to make aware that we have published a new Q&A on Au...
First day of trading in TO 1 in Scandion OncologyIn June/July 2019, Scandion Oncology A/S (“Scandion Oncology”) conducted a ri...
Market Notice 210/19 - Last day of trading in Scandion Oncology A/S"s BTU
Last day of trading in BTU in Scandion OncologyIn June/July 2019, Scandion Oncology A/S (“Scandion Oncology”) conducted a ri...
Significantly oversubscribed rights issue in Scandion OncologyOn July 9, 2019, the subscription period in Scandion Oncology A/S’s ("Scandio...
Scandion Oncology has identified four clinical sites to take part in the planned Phase II clinical trialScandion Oncology A/S (“Scandion Oncology” or the “Company”) today announces ...
SCO-101 is successfully produced as tabletsScandion Oncology A/S (”Scandion”) today announced that SCO-101 tablets have ...
The subscription period in Scandion Oncology"s rights issue begins todayToday, on the 20th of June, 2019, the subscription period for Scandion Oncolo...
Scandion Oncology A/S publishes prospectus in connection with rights issueProspectus relating to the rights issue in Scandion Oncology A/S (”Scandion O...
Market Notice 159/19 - Update - Information regarding the rights issue from Scandion Oncology A/S
Market Notice 152/19 - Information regarding the rights issue from Scandion Oncology A/S
Communique from the Extraordinary General Meeting in Scandion Oncology A/SOn June 11th, 2019, the Extraordinary General Meeting of Scandion Oncology A/...
Scandion Oncology appoints Chairman and Vice-Chairman of its Board of DirectorsScandion Oncology A/S (“Scandion Oncology”) hereby announces that Jørgen Bard...
Main shareholders signs lock-up agreements for 12 monthsIn connection with the announcement that the Board of Directors of Scandion O...
Communique from the Annual General Meeting of Scandion Oncology A/SOn May 29th, 2019, the Annual General Meeting of Scandion Oncology A/S (”Scan...
Notice of Extraordinary General Meeting in Scandion Oncology A/SThe Board of Directors of Scandion Oncology A/S (”Scandion Oncology” or the “...
The board of Scandion Oncology proposes a rights issue to increase the commercial potential for its drug candidates and to expand its drug pipelineScandion Oncology A/S (“Scandion Oncology” or ”the Company”) today announces ...
Interim report 1 January - 31 March 2019Scandion Oncology A/S (”Scandion Oncology” or ”the Company”) hereby publishes...
Scandion Oncology A/S announces new date for publication of interim report January - March 2019Scandion Oncology A/S would like to make use of the full window for releasing...
SCANDION ONCOLOGY A/S obtains "Intention to Grant" notice for SCO-101 from the European Patent Office (EPO)SCANDION ONCOLOGY A/S is pleased to announce that the company has received an...
Notice to Annual General Meeting in Scandion Oncology A/SThe Board of Directors of Scandion Oncology A/S (”Scandion Oncology” or the“C...
Scandion Oncology A/S Annual Report 2018 publishedScandion Oncology A/S hereby publishes the Annual Report for 2018. The Annual...
Scandion Oncology signs collaboration agreement with University of Copenhagen regarding co-development of a class of drug candidates that reverts anti-cancer drug resistanceScandion Oncology A/S (”Scandion” or ”the Company”) announces today that the ...
Scandion Oncology obtains EU Funding for SCO-101 in drug resistant breast cancer patientsScandion Oncology A/S (”Scandion” or ”the Company”) announces today that the ...
Scandion Oncology A/S reports successful meeting with Danish Medicines Agency regarding clinical development of SCO-101 Scandion Oncology and The Danish Medicines Agency have had a very positive ...
Scandion Oncology Signs Contract with Solural Pharma to Formulate SCO-101 Tablets for Clinical Phase II Trial Scandion Oncology A/S and Solural Pharma ApS have entered into an agreement...
Scandion Oncology A/S Obtains Positive Preclinical Results in Antibiotic ResistanceScandion Oncology A/S (Scandion Oncology) hereby announces that Scandion Onco...
Presentation video in relation to year-end reportScandion Oncology has made two videos to present the company and the basic co...
Year End Report for 2018Scandion Oncology has published the Year End Report for 2018. The Press Relea...
Year-end Report 1 January - 31 December 2018Scandion Oncology A/S (”Scandion Oncology” or ”the Company”) hereby publishes...
Senior executives increase their holdings in Scandion OncologyThe increase of shares of senior executives in Scandion Oncology can be viewe...
Disclosure notice
Senior executives increase their holdings in Scandion Oncology A/SScandion Oncology A/S ("Scandion Oncology") today announces that the Chairman...
Scandion Oncology informs on the selection of collaborator for the Boost4Health Internationalisation grantScandion Oncology A/S (“Scandion Oncology”) today announces that the company ...
Interim Report Q3 2018Scandion Oncology A/S (”Scandion Oncology”) herby reports interim report for ...
Scandion Oncology to receive EU support to boost international developmentScandion Oncology A/S has been granted an Impact Voucher of 14.999 EUR from B...
First day of trading in Scandion Oncology A/S shares on Spotlight Stock MarketToday, November 8, 2018, is the first day of trading in Scandion Oncology A/S...
Marknadsmeddelande 260/18- Scandion Oncology A/S noteras på Spotlight Stock Market den 8 november2018Första handelsdag på Spotlight Stock Market för Scandion Oncology A/S aktie ä...
Scandion Oncology A/S new share issue oversubscribedOn October 18, 2018, the subscription period for Scandion Oncology A/S’s ("Sc...
Idag inleds teckningstiden i Scandion Oncology A/S nyemission inför planerad notering på Spotlight Stock MarketIdag, den 4 oktober 2018, inleds teckningstiden i Scandion Oncology A/S ("Sca...
The subscription period for Scandion Oncology A/S new share issue begins todayToday, October 4, 2018, the subscription period for Scandion Oncology A/S ("S...
Scandion Oncology A/S är godkänt för notering på Spotlight Stock MarketScandion Oncology A/S (“Scandion Oncology”) meddelar idag, den 1 oktober 2018...
Scandion Oncology A/S approved for listing at Spotlight Stock MarketToday, Scandion Oncology A/S (“Scandion Oncology”) announces that the company...
Scandion Oncology A/S signs agreement with Sedermera Fondkommission AB regarding an Initial Public Offering at Spotlight Stock Market.Scandion Oncology A/S hereby announces that an agreement has been signed w...
Scandion Oncology A/S hereby announces that an agreement has been signed w...
Saniona Spin-Out, Scandion Oncology Raises DKK 2 Million and Prepares for a Potential Public ListingSaniona, a leading biotech company in the field of ion channels, today announ...
New Saniona spinout focused on cancer therapyScandion Oncology, a spinout from the biotech company Saniona, offers experie...
Saniona satser på spinout-virksomhederDet danske biotekselskab Saniona har netop etableret sin tredje spinout-virks...
Nyt Saniona-spinout har fokus på kræftScandion Oncology, der er en spinout-virksomhed fra biotekselskabet Saniona, ...
